KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $20.3 million.

  • Halozyme Therapeutics' Other Working Capital Changes rose 15279.99% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 370361.53%. This contributed to the annual value of -$5.4 million for FY2024, which is 3069.79% down from last year.
  • As of Q3 2025, Halozyme Therapeutics' Other Working Capital Changes stood at $20.3 million, which was up 15279.99% from $36.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Other Working Capital Changes high stood at $43.5 million for Q2 2024, and its period low was -$38.5 million during Q3 2024.
  • For the 5-year period, Halozyme Therapeutics' Other Working Capital Changes averaged around $3.8 million, with its median value being $2.3 million (2021).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first crashed by 332384.11% in 2023, then soared by 99447.41% in 2024.
  • Halozyme Therapeutics' Other Working Capital Changes (Quarter) stood at $5.0 million in 2021, then crashed by 205.02% to -$5.3 million in 2022, then surged by 122.68% to $1.2 million in 2023, then tumbled by 568.03% to -$5.6 million in 2024, then skyrocketed by 461.48% to $20.3 million in 2025.
  • Its last three reported values are $20.3 million in Q3 2025, $36.1 million for Q2 2025, and $5.0 million during Q1 2025.